Use of Moderate-Intensity Statins for Low-Density Lipoprotein Cholesterol Level above 190 mg/dL at Baseline in...

Area of Science:

• Cardiology
• Pharmacology
• Public Health

Background:

• The ACC/AHA 2013 guideline recommends high-intensity statin therapy for LDL-C reduction >50% in patients with baseline LDL-C ≥190 mg/dL (4.872 mmol/L).
• Adaptation of these guidelines for Korean populations requires investigation due to potential ethnic differences in statin response.

Purpose of the Study:

• To evaluate the statin-specific low-density lipoprotein cholesterol (LDL-C)-lowering effects in Korean patients with a baseline LDL-C value of ≥4.872 mmol/L.
• To determine if moderate-intensity statins can achieve the recommended LDL-C reduction target in this specific demographic.

Main Methods:

• Retrospective analysis of 33,721 patients initiated on statin therapy between January 2009 and December 2013.
• Focused on 179 patients with baseline LDL-C ≥4.872 mmol/L, analyzing laboratory data within six months of initial statin prescription.
• Categorized moderate-intensity statin users into moderate-high and moderate-low intensity groups based on specific drug dosages.

Main Results:

• Among patients with baseline LDL-C ≥4.872 mmol/L, moderate-intensity statins were analyzed.
• LDL-C reduction rates did not significantly differ between moderate-high and high-intensity statin groups (p=0.4895).
• Some moderate-intensity statins achieved >50% LDL-C reduction in this Korean cohort.

Conclusions:

• Moderate-intensity statins can be effective in achieving significant LDL-C reduction (>50%) in Korean patients with high baseline LDL-C.
• The findings suggest a need for re-evaluating and potentially adjusting current ACC/AHA guidelines for statin therapy in Korea.
• Further large-scale, randomized controlled trials are recommended to support the partial reclassification of statins for this patient group.